Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on January 23, 2019, reporting the entry into a material definitive agreement. The filing details a public offering of common stock and warrants that closed on January 25, 2019.
Key Financial Metrics
- Net Proceeds: Approximately $7.6 million received after deducting underwriting discounts, commissions, and estimated expenses.
- Offering Structure: Sale of 10,750,000 shares of common stock and warrants to purchase up to 10,750,000 additional shares.
- Public Price: $0.80 per share combined with one warrant.
- Warrant Terms: Exercise price of $0.80 per share; exercisable immediately; expiration date of January 25, 2024.
- Revenue, Profit, and Debt: The filing text does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the capital raise via the public offering. The company secured approximately $7.6 million in net proceeds, significantly increasing its available liquidity compared to the pre-offering period. No prior comparable period financial data is provided in this specific filing to quantify percentage changes in operational metrics.
Guidance, Outlook, and Use of Proceeds
Management intends to utilize the net proceeds for the following purposes:
- Further development of lead clinical programs.
- Funding clinical development for specific candidates RX-3117 and RX-5902.
- Working capital and general corporate purposes.
The filing does not contain specific forward-looking financial guidance, risk factors beyond standard underwriting representations, or details on unusual items.
Investor Verification Checklist
- Verify the final closing date and exact net proceeds in the subsequent Form 10-Q or 10-K.
- Confirm the status and progress of clinical programs RX-3117 and RX-5902.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.
- Monitor the exercise activity of the 10,750,000 warrants issued.